be the fast to provide the correct answers for me

The APS/AIP response, signed by Harry Lustig, the Treasurer of APS, and Kenneth W. Ford, AIP's Executive Director, was captioned "Gordon & Breach Press Release Is

1527

*1527Misleading." In recapping and defending Barschall's surveys (for which, it noted, he had been given an award by the Association of Research Libraries), the APS/AIP release noted that in Barschall's surveys the G & B journals were found to be "over 30 times more expensive on a cost-per-thousand-character basis than those of the least expensive publisher" in the survey. This casual summary of Barschall's results, G & B contends, constitutes a continuing violation of the Lanham Act's prohibition on misleading advertising.

(3)The 1993 Letter to the Editor:G & B also alleges that another repetition of this statement, in a letter to the editor published in the August 1993 issue ofCBE Views,the bimonthly newsletter of the Council of Biology Editors, Inc., also constitutes a continuing violation. Compl.Ex.F. As with the press release, the letter to the editor (also by Lustig and Ford) constituted a response to an attack on Barschall's surveys in this case, an article in an earlier issue ofCBE Viewsby a private consultant, Albert Henderson, attacking the surveys as inaccurate and as tainted by Barschall's affiliation with APS and AIP. Lustig and Ford's letter was accompanied by a response from Henderson.

Question 1

I'd like to know the possibility of giving these drugs in epileptics:

vincamine (Oxicebral), cinnarizine, piribedil (Trivastal) and

pentoxyphylline (Trental). I'd like to know if they are contraindicated.

Question 2

If an epileptic patient, treated with oxcarbazepine, develops a rash,

should this drug be withdrawn or the dosage decreased and then

increased gradually again?

Question 3

Does a patient with refractory epilepsy benefit from acetazolamide?

Question 4

What anti-epileptic drug is recommended for a child with epilepsy and

co-morbid attention deficit hyperactivity disorder (ADHD)? Can Ritalin

safely be used for treatment?

Question 5

What is the difference in efficacy and pharmacokinetics between sodium

valproate and valproic acid?

Question 6

Is it safe to give valproic acid to infants below 12 months of age?

Question 7

How many times must the liver transaminases (SGOT and SGPT) rise to

justify a discontinuation of valproic acid therapy in children? Which of

these enzymes is more sensitive and reliable in this situation?

Question 8

1. Does valproic acid block the photosensitivity phenomenon in reflex

epilepsy?

2. Can a patient with this photosensitivity be safely exposed to computer

games or other photic stimuli when receiving valproic acid treatment?

3. Does the photosensitivity phenomenon occur in partial seizures?

Question 9

1. Can an epileptic fit be induced in idiopathic and symptomatic focal

epilepsy syndromes by flickering lights?

2. Is valproate effective against the photosensitive phenomenon (seizure

induction by flickering light)?

Question 10

How much time should one give before a loading dose of phenytoin is

judged to be ineffective in controlling seizures and an alternative should

be instituted?101110